Impact of LP.8.1-Adapted mRNA Vaccination on SARS-CoV-2 Variant Neutralisation
Christine, H.; Hoffmann, M.; Metodi V., S.; Inga, N.; Amy, E.; Torsten, W.; Luis, M.; Pöhlmann, S.; Alexandra, D.-J.; Behrens, G. M.
Show abstract
SARS-CoV-2 continues to evolve, with successive variants evading immunity established through prior infection or vaccination. By mid-2025, the XFG lineage emerged and began replacing LP.8.1 across multiple geographical regions, indicating further adaptive evolution within the JN.1-derived clade. We therefore assessed immune responses in 42 healthcare workers who received 30 g of LP.8.1-adapted mRNA vaccine (Comirnaty LP.8.1, BioNTech-Pfizer, Mainz, Germany) in September 2025. Post LP.8.1 vaccination, anti-spike IgG and anti-spike omicron IgG changed 2{middle dot}2-fold and 1{middle dot}9-fold, respectively, revealing significant increases. Neutralising antibody responses against pseudovirus particles (pp) with spike proteins of various SARS-CoV-2 variants revealed a significant increase in neutralisation of JN.1pp (mean change 4{middle dot}2-fold), LP.8.1pp (8{middle dot}2-fold), NB.1.8.1pp (8{middle dot}6-fold), XFGpp (16{middle dot}5-fold), and BA.3.2.2pp (2{middle dot}2-fold). Fold increase in GMT neutralisation post-vaccination was highest for XFGpp whilst absolute post-vaccination neutralisation GMT was lowest for BA.3.2.2pp. Our data suggest that the LP.8.1 mRNA vaccination most likely increases protection against severe disease courses and sequelae of COVID-19 caused by the currently circulating XFG variant. Strengthening humoral immunity against BA.3.2 variants may require further vaccine refinement.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report 95%
- A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152 94%
- Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA 94%
Similar papers in this journal
- Antibody Responses After a Single Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-CoV-2 95%
- The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies. 94%
- Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 94%
Similar papers in this journal
- Durability of antibody responses and frequency of clinical and subclinical SARS-CoV-2 infection six months after BNT162b2 COVID-19 vaccination in healthcare workers 95%
- Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection 94%
- Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2 infection in long-term care facilities in Spain 91%
Similar papers in this journal
- Predicting the efficacy of variant-modified COVID-19 vaccine boosters 95%
- mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant 94%
- Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.